Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory
Belantamab mafodotin (Blenrep) in combination with bortezomib and dexamethasone showed significant survival benefits in relapsed or refractory multiple myeloma (RRMM) patients, meeting overall survival (OS) secondary endpoint in the DREAMM-7 trial. Despite FDA withdrawal in 2022, ongoing DREAMM trials aim to determine its efficacy in combination therapies.
Related Clinical Trials:
J&J Submits sBLA for Guselkumab (Tremfya) Subcutaneous Induction Regimen in UC
Johnson & Johnson submits sBLA for guselkumab SC induction regimen in UC, supported by ASTRO study data. Guselkumab, an IL-23 inhibitor, aims to offer a fully SC induction and maintenance regimen for IBD patients.
TRexBio: $84 Million (Series B) Closed To Decode Human Tissue Immune Biology
TRex Bio closed an $84 million Series B funding round led by Delos Capital, with participation from Avego BioScience Capital, Agent Capital, and existing investors. The funds will advance TRB-061, a TNFR2 agonist, through early clinical trials for immune-mediated diseases like atopic dermatitis and ulcerative colitis, with a Phase 1 trial expected in H1 2025. New board members include Eric Huang, Joel S. Marcus, and Eric Pham.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
Johnson & Johnson submitted an sBLA to the FDA for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis (UC), based on positive findings from the Phase III ASTRO trial. Tremfya, an IL-23 inhibitor, aims to offer a fully subcutaneous induction and maintenance regimen, potentially providing choice and simplicity for patients and providers.
Health Canada issues NOC to J&J's CARVYKTI
Health Canada approves Johnson & Johnson's CARVYKTI as the first B-cell maturation antigen-targeted therapy for multiple myeloma patients, based on Phase III CARTITUDE-4 trial results showing a 74% reduction in disease progression or death risk compared to standard care.
JNJ seeks FDA approval of subcutaneous induction regimen of Tremfya
Johnson & Johnson submits supplemental Biologics License Application to FDA for subcutaneous induction regimen of Tremfya in adults with moderately to severely active UC, supported by Phase 3 ASTRO study data.
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of ...
Johnson & Johnson submits sBLA to FDA for subcutaneous TREMFYA® induction regimen in UC, supported by Phase 3 ASTRO study data, potentially offering choice of SC or IV induction.
Related Clinical Trials:
J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
J&J Innovation Medicine seeks FDA approval for Tremfya's subcutaneous injection initiation in ulcerative colitis, based on Phase III ASTRO study findings. If approved, it would be the first IL-23 inhibitor offering both SC and IV induction options, potentially enhancing treatment accessibility and convenience.
© Copyright 2024. All Rights Reserved by MedPath